Scott Newsome, DO, MSCS, FAAN, president of CMSC, discussed this year’s virtual meeting and how the organization chose to focus on the health care team in multiple sclerosis.
Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2020 Meeting reviewing first-line ocrelizumab compared to glatiramer acetate and dimethyl fumarate for treatment of relapsing-remitting multiple sclerosis.
In the post hoc analysis from the phase 3 ASCLEPIOS I and II trials presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2020 Annual Meeting, subcutaneous ofatumumab is compared with oral teriflunomide in relapsing multiple sclerosis.
